Langenickel, Thomas H.
Jordaan, Pierre
Petruck, Jesika
Kode, Kiran
Pal, Parasar
Vaidya, Soniya
Chandra, Priya
Rajman, Iris
Funding for this research was provided by:
Novartis
Article History
Received: 27 January 2016
Accepted: 10 April 2016
First Online: 16 April 2016
Compliance with ethical standards
: The study protocol was approved by the Ethics Committee of the study center. The study was designed and implemented in accordance with the ICH Guidelines for Good Clinical Practice E6 [CitationRef removed] and for Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14 [CitationRef removed], applicable local regulations, and the ethical principles laid down in the Declaration of Helsinki.
: THL, PJ, PP, SV, and IR are employees of Novartis. JP and PC were employees of Novartis at the time this study was conducted.